<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01771705</url>
  </required_header>
  <id_info>
    <org_study_id>NFAT dependent cytokines</org_study_id>
    <nct_id>NCT01771705</nct_id>
  </id_info>
  <brief_title>NFAT-Dependent Cytokine Gene Expression for Immune Monitoring in Kidney Transplant Patients</brief_title>
  <official_title>NFAT-Dependent Cytokine Gene Expression for Immune Monitoring in Kidney Transplant Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare two different ways of monitoring the immune system to
      determine how to manage the doses of anti-rejection medications.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single center randomized controlled trial investigating the efficacy and safety of
      adjusting calcineurin inhibitor (CNI) dosing based on Nuclear Factor of Activating T Cells
      (NFAT)-dependent cytokine gene expression as compared to standard of care adjustments based
      on trough level. Before any study-related evaluations are performed, the patient must give
      written informed consent. Once consent is obtained, a patient's eligibility to participate in
      the study will be assessed within 2 weeks of their 6 month management biopsy. Approximately
      40 patients who meet inclusion criteria will be randomized at University of California, San
      Francisco (UCSF). Eligible patients include any patient maintained on triple therapy with
      tacrolimus, mycophenolate mofetil ,and prednisone who has had no prior rejection episodes and
      who has undergone a 6 month management kidney biopsy that shows no evidence of acute cellular
      rejection or antibody mediated rejection.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">January 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>•Number of adjustments made to tacrolimus regimen at 6 months; •Lack of correlation between NFAT-dependent cytokine expression and tacrolimus trough levels</measure>
    <time_frame>6 Months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>1 year (18 months post-transplant) biopsy proven acute rejections episodes</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1 year (18 months post-transplant) cumulative infectious complications</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1 year (18 months post-transplant) GFR</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1 year (18 months post-transplant) allograft survival</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1 year (18 months post-transplant) patient survival</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Kidney Transplantation</condition>
  <arm_group>
    <arm_group_label>Dose adjust group (NFAT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Within 2 weeks of a 6 month management biopsy, if eligibility is confirmed, NFAT dependent cytokines including IL-2, IFNg, and GMCSF at times C0 and C1.5 will be performed with the residual expression calculated based on the ratio of C1.5/C0 x 100%. If the average residual expression of the 3 cytokines is &lt;15%, the CNI daily dose will be reduced by 15%. If the average residual gene expression of the 3 cytokines is &gt; 80% the CNI daily dose will be increased by 15%.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of care group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>A CNI trough level will be obtained. Adjustments of CNI will be based on target trough drug levels as per standard of care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Dose adjust group (NFAT)</intervention_name>
    <description>If the average residual expression of the 3 cytokines is &lt;15%, the CNI daily dose will be reduced by 15%. If the average residual gene expression of the 3 cytokines is &gt; 80% the CNI daily dose will be increased by 15%.</description>
    <arm_group_label>Dose adjust group (NFAT)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: Eligible patients include any patient maintained on triple therapy with
        tacrolimus, mycophenolate mofetil ,and prednisone who has had no prior rejection episodes
        and who has undergone a 6 month management kidney biopsy that shows no evidence of acute
        cellular rejection or antibody mediated rejection.

        Exclusion Criteria: Any patient not maintained on triple therapy with tacrolimus,
        mycophenolate mofetil and steroids and/or who had evidence of rejection on 6- month
        management biopsy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Flavio Vincenti, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Allison Webber, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Giese T, Sommerer C, Zeier M, Meuer S. Monitoring immunosuppression with measures of NFAT decreases cancer incidence. Clin Immunol. 2009 Sep;132(3):305-11. doi: 10.1016/j.clim.2009.03.520. Epub 2009 Apr 23.</citation>
    <PMID>19398376</PMID>
  </results_reference>
  <results_reference>
    <citation>Giese T, Zeier M, Schemmer P, Uhl W, Schoels M, Dengler T, Buechler M, Meuer S. Monitoring of NFAT-regulated gene expression in the peripheral blood of allograft recipients: a novel perspective toward individually optimized drug doses of cyclosporine A. Transplantation. 2004 Feb 15;77(3):339-44.</citation>
    <PMID>14966405</PMID>
  </results_reference>
  <results_reference>
    <citation>Sommerer C, Giese T, Schmidt J, Meuer S, Zeier M. Ciclosporin A tapering monitored by NFAT-regulated gene expression: a new concept of individual immunosuppression. Transplantation. 2008 Jan 15;85(1):15-21. doi: 10.1097/01.tp.0000296824.58884.55.</citation>
    <PMID>18192906</PMID>
  </results_reference>
  <results_reference>
    <citation>Sommerer C, Zeier M, Meuer S, Giese T. Individualized monitoring of nuclear factor of activated T cells-regulated gene expression in FK506-treated kidney transplant recipients. Transplantation. 2010 Jun 15;89(11):1417-23. doi: 10.1097/TP.0b013e3181dc13b6.</citation>
    <PMID>20463649</PMID>
  </results_reference>
  <results_reference>
    <citation>Hartmann B, Schmid G, Graeb C, Bruns CJ, Fischereder M, Jauch KW, Heeschen C, Guba M. Biochemical monitoring of mTOR inhibitor-based immunosuppression following kidney transplantation: a novel approach for tailored immunosuppressive therapy. Kidney Int. 2005 Dec;68(6):2593-8.</citation>
    <PMID>16316335</PMID>
  </results_reference>
  <results_reference>
    <citation>Leogrande D, Teutonico A, Ranieri E, Saldarelli M, Gesualdo L, Schena FP, Di Paolo S. Monitoring biological action of rapamycin in renal transplantation. Am J Kidney Dis. 2007 Aug;50(2):314-25.</citation>
    <PMID>17660033</PMID>
  </results_reference>
  <results_reference>
    <citation>Belouski SS, Wilkinson J, Thomas J, Kelley K, Wang SW, Suggs S, Ferbas J. Utility of lyophilized PMA and ionomycin to stimulate lymphocytes in whole blood for immunological assays. Cytometry B Clin Cytom. 2010 Jan;78(1):59-64. doi: 10.1002/cyto.b.20492.</citation>
    <PMID>19777549</PMID>
  </results_reference>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 16, 2013</study_first_submitted>
  <study_first_submitted_qc>January 16, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2013</study_first_posted>
  <last_update_submitted>May 20, 2016</last_update_submitted>
  <last_update_submitted_qc>May 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Transplantation</keyword>
  <keyword>Kidney</keyword>
  <keyword>calcineurin inhibitor</keyword>
  <keyword>NFAT</keyword>
  <keyword>tacrolimus</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

